HTT and Huntington disease: For HD, several recombinant antibodies and intrabodies have been raised against translation products of HTT exon1, and it is now apparent that the ability of anti-HTT intrabodies to modulate aggregation and its associated neurotoxicity depends strongly on the epitope of HTT toward which they are directed [48].